Recombinant Human Ad-p53

重组人p53腺病毒

Report date: 2023/10/26 16:02:53

Base Information

Drug NameRecombinant Human Ad-p53
Drug Alias Name重组腺病毒-p53抗癌注射液rAD-p53 - Shenzhen SiBiono GenTech今又生GendicineSBN-1 +[6] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vectorBiologics > Oncolytic virus
Mechanisms of ActionTumor protein p53 stimulants
TargetsTumor protein p53
Therapy Area/IndicationsPrecancerous ConditionsFallopian Tube NeoplasmsMultiple Pulmonary Nodules +[7] 
Global Approved IndicationsNasopharyngeal Neoplasms
Approved Indications in ChinaNasopharyngeal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2004/01/20
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenzhen SiBiono GeneTech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen SiBiono GeneTech Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecancerous ConditionsMultiple Pulmonary NodulesLung Neoplasms +[4] 
Inactive IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial

Other Information

ATC CodeL01XX
Related LinksWikipedia